Michael York
Geen lopende functies
Vermogen: 59 629 $ op 31-05-2023
Profiel
Michael York served as President & Chief Executive Officer at Sente, Inc. from 2013 to 2014.
He was Vice President-Specialty & Rare Disease Unit at Amylin Pharmaceuticals, Inc. He also served as Vice President-Global Business Development at Orexigen Therapeutics, Inc. from 2015 to 2018.
From 2018 to 2021, he was Vice President-Development & Commercial Strategy at PhaseBio Pharmaceuticals, Inc. He served as President & Chief Executive Officer at SENTÉ Labs.
In 2021, he became President, CEO, CFO, Secretary & Treasurer at Metacrine, Inc. Mr. York received his undergraduate degree from San Diego State University and his MBA from the University of Redlands.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
METACRINE INC
0.25% | 03-02-2023 | 107 054 ( 0.25% ) | 59 629 $ | 31-05-2023 |
Eerdere bekende functies van Michael York
| Bedrijven | Functie | Einde |
|---|---|---|
| METACRINE, INC. | Chief Executive Officer | 24-03-2023 |
| PHASEBIO PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01-11-2021 |
| OREXIGEN THERAPEUTICS, INC. | Corporate Officer/Principal | 01-06-2018 |
| Sente, Inc. | Chief Executive Officer | 01-12-2014 |
| SENTÉ Labs | Chief Executive Officer | - |
Opleiding van Michael York
| San Diego State University | Undergraduate Degree |
| University of Redlands | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| PHASEBIO PHARMACEUTICALS, INC. | Health Technology |
| METACRINE, INC. | Health Technology |
| Bedrijven in privébezit | 4 |
|---|---|
Amylin Pharmaceuticals, Inc.
 Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA. | Health Technology |
Orexigen Therapeutics, Inc.
 Orexigen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Orexigen Therapeutics, Inc. is a biopharmaceutical company, which focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its primary activities include recruiting personnel, conducting research and development, including clinical trials, raising capital, and preparing for the marketing and commercialization of its product, contrave. The company was founded by Eckard Weber in September 2002 and is headquartered in La Jolla, CA. | Health Technology |
| Sente, Inc. | Technology Services |
| SENTÉ Labs |
